Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory CD30-positive lymphomas treated with Tessa's "off the shelf" CD30.CAR
Investegate announcements from Tessa Therapeutics Ltd, Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
New data from clinical trials of TT11 and TT11X to be featured in two oral podium presentations and a poster presentationSINGAPORE, Nov. 03, 2022 (Tessa), a clinical-stage cell therapy company developing